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ABSTRACT 
Background: Pancreatic cancer is a devastating disease with limited treatment options. Over 
80% of pancreatic cancers are diagnosed in advanced stages and often have debilitating 
symptoms, making symptom management paramount; yet, the symptom experience of patients 
with advanced pancreatic cancer (APC) is not well understood.  
Objective: The purpose of this integrative review was to synthesize the current evidence 
regarding the symptom experience of patients with APC.   
Method: An integrative literature review was conducted to identify the patient symptom 
experience in studies published from 2005 to 2015.  
Results: Sixteen studies met the inclusion criteria. All studies used a quantitative approach; 44% 
were quasi-experimental, 31% were descriptive, and 25% were correlational. Physical 
symptoms, especially pain, were the primary focus in most studies. Fatigue, loss of appetite, and 
impaired sense of well-being were prevalent and reported by patients to be of high intensity. Few 
studies examined psychological symptoms in patients with APC, though anxiety and depression 
were noted. 
Conclusion: Findings suggest that physical and psychological symptoms are prevalent, some 
with high intensity. Pre-selection of symptom inventories limits our ability to fully understand 
the symptom experience of patients with APC. Future qualitative work is needed to provide a 
more in-depth understanding of symptoms, especially symptom quality and distress level, from 
patients’ perspectives. More studies are needed to explore psychological symptoms and the 
interaction of physical and psychological symptoms.  
Abstract
Implications for practice: Findings help health care givers to better understand the symptom 
experience of their APC patients.  
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Introduction   
Pancreatic cancer is one of the most challenging types of cancer because there are no 
effective prevention or early detection methods and treatment options are limited. Pancreatic 
cancer ranks fourth as a cause of cancer deaths, with over 40,500 estimated deaths for 2015 in 
the United States.1 By 2030, scientists predict that pancreatic cancer will be the second leading 
cause of cancer death.2 Despite significant improvement in survival rates for many types of 
cancer, the death rate for pancreatic cancer has slowly increased over the past decade. In fact, the 
overall five-year survival rate for patients in the advanced stage is approximately only 2%.1, 3  
The complexity of the disease and treatment and the rapid physical deterioration pose 
special challenges to symptom management for patients with advanced pancreatic cancer (APC). 
Symptoms, which are the “perceived indicators of change in normal functioning as experienced 
by patients,”4(pp68) may be both complex and severe and significantly impact health related 
quality of life (HRQOL). For patients with APC and their caregivers, symptom management is 
the primary goal of care. Yet, though some studies have begun to focus on special symptoms or 
symptom clusters among different critically ill cancer populations, such as leukemia and lung 
and ovarian cancer,5-7 little is known about the symptom experience of patients living with APC. 
Emphasis has been placed on developing or evaluating treatment methods rather than symptom 
management.  
There is a lack of comprehensive and systematic approaches to understanding symptoms 
and their impact in patients with APC. This knowledge gap not only contributes to poor 
symptom management but also ignores how symptoms interfere with patients’ survival duration, 
HRQOL, psychological health, communication, decision making, and preparing for death.4, 8 
Furthermore, because of the quick disease progression, APC is an ideal prototype to understand 
symptom changes and care needs in patients who face rapid transition from healthy status to 
terminal illness.9, 10 Therefore, the purpose of this integrative review was to synthesize current 
evidence regarding APC patients’ symptom experiences. Findings from this review will inform 
future research directions and help health care providers design comfort measures that support 
patients as they manage and cope with symptoms. 
Methods 
This integrative review was designed to fully examine the symptoms experienced by 
patients with APC and used the methodological strategies proposed by Whittemore and Knafl 
(2005).11 An integrative review was selected because it allowed us to include heterogeneous 
resources such as different research methods and varying data collection instruments.  The steps 
of the review included 1) problem identification, 2) literature search, 3) data evaluation, 4) data 
analysis, and 5) presentation of findings.       
Literature Search  
Literature describing the symptom experience of patients with APC was identified by 
searching in four databases: Pubmed, Cumulative Index to Nursing and Allied Health Literature 
(CINAHL), Embase, and PsychINFO. We used two medical subject heading searches to find 
citations in Pubmed: 1) “pancreatic neoplasms” AND “symptom assessment” OR quality of life” 
and 2) “pancreatic neoplasms,” “signs and symptoms,” AND “terminal care.” The CINAHL 
headings of “pancreatic neoplasms” AND “symptoms” OR “quality of life” were used to search 
in the CINAHL, and the Emtree terms of “pancreas cancer,” “terminally ill patients,” AND 
“symptoms” OR “quality of life” were used to search in Embase. Emtree terms are hierarchically 
structured terminologies which are used to index the Embase content. For PsychINFO, subject 
terms of "neoplasms," "pancreas," AND "symptoms” OR “quality of life" were used. In addition 
to subject terms, we also used key words (i.e., “pancreatic cancer” AND “stage three” OR “stage 
four” OR terminal OR palliative) AND (symptoms OR signs OR “quality of life”)) to search 
aforementioned databases. Search limitations were English language, human sample, and year 
published (2005-2015) since treatment protocols for APC advance quickly. Each journal article’s 
reference list was also carefully searched by hand to identify additional pertinent articles. The 
search results were imported into EndNote X7.5 and duplicates were removed. We then 
reviewed the titles, abstracts, and full text of the articles based on the inclusion and exclusion 
criteria to determine their eligibility.     
Inclusion and exclusion criteria. Based on the theoretical definition of symptom experience in 
Armstrong’s concept analysis and Lenz’s Theory of Unpleasant Symptoms, only the patient can 
report on the symptom experience, including its four dimensions: intensity, timing, quality, and 
distress.4, 12 Therefore, manuscripts included in this review include quantitative, qualitative, and 
mixed-methods studies focusing on physical or psychological symptoms experienced and 
reported by patients with APC.  APC patients were defined as patients diagnosed with locally 
advanced or distant pancreatic cancer that was not eligible for curative surgery at diagnosis. We 
also included studies with heterogeneous cancer patient populations only if the results for those 
with APC were analyzed separately. 
We excluded manuscripts that: (1) did not report on empirical studies, including opinions, 
case reports, or editorials; (2) were review articles; (3) did not include patient “self-report” of 
symptoms; or (4) only addressed symptoms related to a specific drug or procedure because the 
foci of these articles were on drug toxicity or safety/effectiveness of the procedure versus overall 
symptom experiences. Moreover, studies focused only on specific drug- or procedure-related 
symptoms often set inclusion criteria of particular symptom intensity (e.g., patients with 
moderate pain).  
Data Extraction   
We used an author-developed data coding sheet to conduct the two steps of data extraction. 
First, we extracted information regarding authors, year of publication, setting characteristics, 
participant characteristics, and study design. Second, we extracted information with regard to 
symptom-related variables based on the aforementioned concept analysis and theoretical 
framework. Second, the symptom-related variables, including type of symptom, measurement 
instruments, symptom profile (symptom intensity, timing, quality, and distress), and associated 
factors were identified. The four dimensions of symptom profile were defined based on the 
Theory of Unpleasant Symptoms.4 Specifically, symptom quality is related to characteristics of 
symptoms (e.g., “burning” pain). Symptom intensity quantifies the degree, strength, or severity 
of symptoms. Timing is related to the occurring time, duration, and frequency. The distress 
dimension refers to the affective aspect or meaning of symptoms.4 After reading the articles, two 
of the authors (C. T. & D. V.) highlighted relevant information and organized information using 
the coding sheet. We further created several tables to contrast and compare variables. Tables are 
presented along with findings in the next paragraph.  
Findings 
Nine hundred and sixteen articles were initially identified. After removing duplicates 
(n=90), the remaining 826 articles were screened by titles, which resulted in a total of 337 
articles remaining. After screening the 337 abstracts using the established criteria, 293 articles 
were excluded. Among the 293 articles, 44% (n=128) did not report results specific to an APC 
population; 36 % (n=106) were non-empirical, non-peer-reviewed, or review articles; 16% 
(n=47) did not include patient-reported symptoms; and 4% (n=12) only addressed symptoms 
related to a specific drug or procedure. Among the 44 articles that were retained for full-text 
review, 29 were excluded because they (1) did not include patient-reported symptoms (n=11), (2) 
only addressed symptoms related to a specific drug or procedure (n=11), (3) did not report results 
specific to an APC population (n=6); and/or (4) were not written in English (n=1). A hand search 
of each manuscript’s reference list resulted in adding one more article. Thus, a total of 16 studies 
was included in the analysis (Figure 1).  
All 16 studies were quantitative, with five descriptive studies,13-17 four correlational 
studies,18-21 and seven quasi-experimental studies.22-28 Six of the 16 studies (37.5%) explored 
overall symptom experiences or the relationship among symptoms in patients with APC,15, 17-21 
and two studies (12.5%) compared symptom experiences across different pancreatic cancer 
stages.13, 16 Five studies (31.25%) focused on pain or pain management strategies for patients 
with APC,14, 22, 23, 27, 28 and the remaining three studies (18.75%) focused on interventions other 
than pain management.24-26 Only 2 of the 16 studies explicitly described a guiding theory or 
framework. The theoretical frameworks utilized were systematic inflammation17 and descriptions 
of nociceptive and neuropathic pain.14 The number of study participants ranged from 20 to 654, 
and the APC patients’ medium survival duration for those articles that reported on this variable 
(n=8) was about 6.36 months (range from 3.5 to 8.9 months). About half (n=8) of the studies 
were conducted in Europe15, 17, 18, 21-24, 26 and the other half in North America (n=7).13, 14, 16, 19, 20, 
25, 27 One study was conducted in Asia.28 Table 1 displays study aims, designs, population, and 
symptom-related results. From our review, we organized the studies by symptom types and 
instruments, symptoms identified, symptom profiles, and factors associated with symptoms.  
Instruments  
All studies used instruments to evaluate pre-determined symptoms. The 9 instruments 
used in the 16 studies were in two categories: one focused on evaluating cancer patients’ 
multiple symptoms and HRQOL and the other focused solely on pain. Six instruments that focus 
on multiple symptoms are the European Organization for Research and Treatment of Cancer 
(EORCT QLQ-C30) with or without the pancreatic special module (EORCT QLQ-PAN26), the 
Edmonton Symptom Assessment Scale (ESAS), the European Quality of Life-5 Dimensions 
(EQ-5D), the Functional Assessment of Cancer Therapy general module (FACT-G) with or 
without the hepatobiliary module (FACT-HEP), the Linear Analog Scale Assessment (LASA), 
and the M.D. Anderson Symptom Inventory (MDASI). Table 2 displays the symptom inventory 
captured by these six instruments. Three instruments focused solely on pain are the McGill 
Melzack Pain Questionnaire,14 the Brief Pain Inventory (BPI),22 and a single item for rating pain 
intensity and frequency.24 Overall, the EORTC QLQ-C30 and/or EORTC QLQ-PAN26 were the 
most frequently used measurement tools (n=8),13, 15, 17, 18, 20, 23, 26, 27 followed by the FACT-G 
(n=2).16, 22 Though investigators used a variety of different instruments to measure symptoms, 
some symptoms are included in instruments more often than others. Specifically, almost all 
symptom evaluation instruments measured pain and depression symptoms. However, taste 
change, numbness, and most psychological symptoms were addressed by only one or two 
instruments.  
Symptoms Identified 
All studies identified physical symptoms, and nine of the 16 (56.25%) studies13, 15, 17-19, 21-
23, 25 also covered psychological symptoms. Table 3 shows authors, the symptoms reviewed, and 
measurement instruments. Importantly, Table 3 also displays the problematic symptoms 
identified by each study and the corresponding operational definitions of problematic symptoms. 
The physical symptoms identified in the APC samples were pain, fatigue/lack of energy, loss of 
appetite, dry mouth, taste change, digestive problems (e.g., nausea, vomiting, altered bowel 
habits, indigestion, and flatulence), respiratory problems (e.g., dyspnea), and poor sleep. The 
psychological symptoms were related to sense of well-being, anxiety, depression/sadness, 
emotional distress/mood disturbance, life enjoyment, and fear. Congruent with our previous 
observation that all instruments measured pain, pain was the most prevalent symptom discussed 
in all studies, followed by fatigue (n=11, 68.75%), digestive symptoms (n=9, 56.25%), and loss 
of appetite (n=7, 43.75%). However, although depression was also included in most instruments 
used, it was only discussed in six (37.5%) of the studies.   
Symptom Profile: Intensity, Timing, Quality, and Distress  
In this section, we report APC patients’ symptom profiles using the Theory of Unpleasant 
Symptoms’ four dimensions: intensity, timing, quality, and distress. The majority of the studies 
found that patients with APC had substantial physical and psychological symptoms, especially as 
related to the intensity dimension.13, 15-28 Compared to the healthy population and early stage 
pancreatic cancer population, patients with APC reported more total symptoms and more intense 
symptoms such as fatigue, appetite loss, pain, digestive symptoms (e.g., indigestion), anxiety, 
and depression.13, 15, 16, 25 Although the researchers used various instruments with different 
operational definitions to determine the level of intensity of symptoms, they reported that a 
considerable number (more than 25%) of patients experienced moderate to severe intensity of 
symptoms that included fatigue,15, 18-20, 26-28 loss of appetite,15, 18-20, 26-28 pain,13, 15, 19, 20, 24-27 
insomnia,20, 26-28 digestive symptoms,13, 26-28 impaired sense of well-being,15, 18 anxiety and 
depression,25 and fear.13 Fatigue, loss of appetite, and pain were the top three severe symptoms 
reported.  
Eleven studies explored fatigue, and most of these reported patients’ average fatigue 
intensity was moderate to severe.15, 18-20, 26-28,  In those articles that provided more specific 
information, 19% to 63% patients experienced moderate to severe fatigue.15, 17-19 Similarly, 
studies examining loss of appetite (n=7) reported the average intensity of appetite loss was 
moderate to severe,15, 18-20, 26-28 with about 24% to 63% of patients in those articles giving that 
information having loss of appetite that was moderate to severe.15, 18, 19 With regard to pain, 
patients experienced moderate to severe pain on average regardless of treatment types or disease 
progression.13, 15, 20, 26 Specifically, 15%-43% of patients with APC reported moderate to severe 
pain.17-19, 24 Symptom intensity changed along with treatment and disease progress. Though 
pain20, 27, 28 and insomnia20, 27, 28 improved significantly after treatments (e.g., celiac plexus block 
surgery), the intensity of several physical symptoms including fatigue, 28 digestive symptoms,15, 
18, 26, 28 dyspnea15, and dry mouth15 worsened with general care, palliative resection, or celiac 
plexus block surgery. For loss of appetite, some studies found a significant improvement after 
celiac plexus block surgery;27, 28 and other studies demonstrated that the symptom got worse with 
general care and palliative bypass surgery.20, 26   
Among the studies reporting psychological symptoms (n=9), the focus was on sense of well-
being,15, 18, 23 depression,15, 17-19, 22, 25 and anxiety.15, 18, 29 Two studies found that patients with 
APC experienced moderate to severe impairment in their sense of well-being, which worsened as 
the disease progressed.15, 18 Studies presented contradictory findings regarding depression. Some 
showed that most patients experienced mild depression, with mean intensity scores of 2 to 3 out 
of 10,15, 19 whereas others showed that about 40% of patients experienced moderate to severe 
depression.17, 18 Similarly, Bye and colleagues (2013) found that 37-44% patients experienced 
moderate to severe intensity of anxiety, although the mean intensity score for anxiety reported by 
Labori et al. (2006) was at a mild level. Regardless of the intensity level, Romanus et al. (2012) 
reported that more than half of the patients experienced anxiety and depression. When the 
disease progressed, the intensity of anxiety and depression stayed the same or slightly 
increased.15, 18 Most studies used EORTC QLQ-C30 to measure anxiety and depression.15, 17, 18 
Three studies examined the timing dimension of the symptoms, including frequencies24 and 
possible coexisting symptoms or symptom clusters.17, 19 Muller et al. (2008) reported that 51% of 
the patients with APC had daily pain. For the coexisting symptoms, Reyes-Gibby et al. (2007) 
reported all possible symptoms, but Laird and colleagues (2011) focused on the common 
symptom cluster of pain, fatigue, and depression in cancer patients. These two studies found that 
about 24% to 51% of the patients had two or more coexisting symptoms with moderate to severe 
levels of intensity. The proportion of patients with such symptoms tended to increase temporarily 
during chemoradiation.19 Specifically, researchers identified two possible symptom clusters. 
Laird et al. reported more than double the number of patients who would have been expected to 
have had the symptom combination of pain, fatigue, and depression if the symptoms were to 
coexist by chance. Reyes-Gibby et al. (2007) reported a strong relationship between fatigue and 
loss of appetite.  Only one study explored how patients described their symptom quality 
verbally.14 With a very small sample size, Dobratz (2008) could not distinguish pain patterns 
(e.g., nociceptive vs. neuropathic pain) based on APC patients’ word choices. No study explored 
the distress dimension of the symptoms.  
 Factors Associated with Symptoms 
A number of factors were noted to play into APC patients’ symptom experiences. 
Researchers found that fatigue, loss of appetite, pain, and mood were significantly associated 
with other factors such as comorbidity, mortality, function or performance level, energy intake, 
psychological status, HRQOL, social relationships, and survival duration. Specifically, fatigue 
was negatively associated with energy intake and predicted the interference levels of walking, 
activity, work, enjoyment of life, and survival.18, 19, 21 Loss of appetite was not only linked to 
physical function such as energy intake, walking, and activity, but it also predicted psychological 
function including mood and enjoyment of life.18, 19 Pain was negatively related to performance, 
energy intake, and relationships with other people.18, 19, 21, 22 One study further indicated that pain 
intensity can predict survival in patients receiving chemotherapy. In this study, researchers also 
found that poor performance was associated with impaired mood.21 Low energy intake and 
complex comorbid medical conditions were linked to higher overall symptom intensity.18, 19  
Discussion 
The purpose of this review was to synthesize current evidence regarding APC patients’ 
symptom experiences. Based on the 16 reviewed studies, all using a quantitative approach with a 
pre-determined symptom inventory, our main findings were that patients with APC experienced 
multiple intense physical symptoms, especially fatigue, loss of appetite, and pain. With limited 
and inconsistent study results, APC patients’ experiences regarding psychological symptoms 
remains unclear. Similarly, evidence of coexisting symptoms or symptom clusters in the APC 
population is limited. However, current evidence suggests that coexisting symptoms exist. 
Although there is no qualitative study met our inclusion criteria, qualitative evidence supported 
one of our main findings: patients with APC incur a number of complex symptoms that can 
become debilitating. Qualitative studies exploring terminal pancreatic cancer patients’ concerns 
showed that patients and their caregivers experienced several symptoms and expressed their 
great concerns about both physical and psychological symptoms.30, 31 The following paragraphs 
further discuss findings in depth with several identified knowledge gaps. 
 First, the use of various symptom measurement instruments makes it difficult to compare 
identified symptoms and symptom intensity across studies. Instrument variation is especially 
problematic when interpreting psychological symptoms because every instrument uses different 
terms and definitions in relation to psychological symptoms (e.g., depression and sadness). 
Instruments such as LASA measure psychological symptoms using one general term (i.e., mood) 
to capture patients’ experience with regard to depression, anxiety, and stress. Furthermore, all 
reviewed studies only focused on intensity dimension of predetermined symptoms because of 
forced-choice instruments and might ignore other symptoms and other symptom dimensions 
such as quality and distress. Another problem with regard to the instrument is that using the 
instruments designed to measure HRQOL to evaluate symptoms, as most of our reviewed articles 
did, causes difficulties in understanding and managing nutrition-related symptoms.32  
Second, although our results show that fatigue, loss of appetite, and pain were prevalent and 
intense physical symptoms reported by the patients across studies, these symptoms received 
disproportionate attention. It is not surprising that pain has been the major focus of studies since 
pancreatic cancer is widely known to be one of the most painful malignancies.33 All reviewed 
studies addressed pain and about half of them focused on pain management strategies. In 
contrast, only half or fewer of the studies mentioned other problematic physical symptoms (e.g., 
fatigue or loss of appetite) and their symptom management strategies. Our review found that 
fatigue is a prominent and severe problem in the APC population, which corresponds to existing 
assumptions in all cancer population.34 On the other hand, there is a growing recognition that 
loss of appetite is one of the most distressing symptoms for APC and their caregivers, but is 
often overlooked by health care professionals.35-37 Although the etiology of loss of appetite is 
multifactorial and not fully understood, the experience and management of loss of appetite can 
be particularly complicated for patients with APC because it may be associated not only with 
treatment and physical deterioration but also with reduced pancreatic function (e.g., pancreatic 
exocrine insufficiency) and depression,18, 37 which is a prevalent symptom in this context.38 The 
disproportion emphasis of physical symptoms is not only obvious in research but also observable 
in the clinical practice. Two articles which reported the most significant problems faced by 
health care providers when caring patients with APC only discussed pain and anorexia-
cachexia.39, 40 Other studies showed that while pain management has been noted as the most 
frequent intervention provided in the hospice consultation for patients with APC, nutrition 
related evaluation and intervention was documented in less than 15% of the charts.41, 42 This 
ignorance of non-pain symptoms prohibits health care providers from understanding APC 
patients’ symptom profile fully and addressing their needs. A qualitative study reported that 
pancreatic cancer patients expressed their lack of knowledge, confidence, resource access, and 
effective communication with health care providers when managing their digestive symptoms.32  
Our limited understanding of these problematic symptoms may also partly explain why there are 
still no effective symptom management strategies for the majority of the symptoms, although 
APC patients experienced these intense symptoms until death. For example, whereas general 
treatments (e.g., chemotherapy) and pain management surgeries (e.g., nerve block) improved 
pain and insomnia, fatigue and digestive symptoms did not change or even worsened. Studies 
pointed out that the severe symptoms continuously contribute to APC patients’ poor functional 
status and HRQOL with nutrition and digestion symptoms and fatigue being the most significant 
symptoms affecting HRQOL.32, 41, 43 
Third, psychological symptoms also have received insufficient attention. Only about half of 
the studies addressed psychological symptoms, and there was little in-depth exploration or 
discussion. Our findings showed different symptom profiles of psychological symptoms and, 
because of the limited number of studies looking at these symptoms, cannot either support nor 
reject the mounting evidence of strikingly high psychological distress rates in pancreatic cancer 
population compared to other types of cancer.38, 44, 45 For example, although two reviewed 
studies17, 18 found that depression was a severe problem, with approximately 33-50% of the 
pancreatic cancer patients experiencing depression,38 other researchers15, 19 concluded that 
depression is mild in APC population. These different results may be because of different 
measurement methods (e.g., mean symptom score vs. the percent of patients with a high 
symptom score). However, our results do support that psychological distress is elevated when 
disease progresses over time.46 
Despite the insufficient evidence, qualitative evidence suggested that psychological distress 
bothers APC patients and their caregivers. Researchers analyzing the types of questions asked by 
terminal pancreatic cancer patients and their caregivers online indicated that 11-23% of the 
questions were related to psychological concerns.30, 47 Interestingly, while maintaining hope is 
one of the main themes identified with regard to pancreatic cancer patients’ experience,48 only 
one instrument was used by our sample studies that evaluates hope. None of our sample studies 
addressed hope in their result or discussion. Although the evidence is not enough to determine 
the possible cause of psychological symptoms in pancreatic cancer,49, 50 it is clear that there is a 
complicated relationship among patients’ physical symptoms, physical symptoms, and health 
related outcomes. A qualitative study demonstrated that nearly all patients expressed feelings of 
anger, frustration, and powerless related to the lack of knowledge of symptoms, unfamiliarity of 
symptom management strategies, and poor symptom control.32 Researchers suggested that the 
psychological distress is significantly related to poor QOL, fatigue, pain, and loss of appetite in 
pancreatic cancer population.44   
Fourth, with only three studies exploring pain frequencies and co-existing symptoms, we 
know little about the timing dimension of the symptoms. Although our findings suggest that 
symptom clusters may exist, more evidence is needed to determine if there is any unique 
symptom cluster that is associated with APC. Lastly, we have almost no clues regarding the 
quality and distress dimension of the symptoms since only one article discussed pain quality and 
no study explored symptom distress.   
Conclusion 
To our knowledge, this is the first integrative review to explore symptom experiences of 
patients living with APC. By synthesizing the important evidence and highlighting the 
knowledge gaps, this review has important implications for both clinical and research practice. 
For clinical practice, the review findings help to target problems for improved symptom 
management in APC patients. Furthermore, we have identified pressing needs to raise awareness 
of and design interventions for a number of poorly managed and severe symptoms. For future 
research, given that quantitative methodology has been the predominant approach to examine 
symptom experience of patients with APC to date, qualitative studies are needed to explore the 
multiple dimensions of symptoms.  For both researchers and clinicians, it is imperative to focus 
on psychological symptoms, which are still underexplored yet were the main concerns 
mentioned by patients and caregivers during patient-health care provider discussions.47 Studying 
psychological symptoms will facilitate a deeper understanding of the high psychological distress 
rate and the causes so that interventions to alleviate this distress can be developed.  
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Table 1. Summary of the Reviewed Studies 
 
First author 
(year of 
publish) 
Study aim  Study design  Population 
(n=number of 
study participants) 
Symptom related results [measurement tool] 
Allen 
(2011) 
To assess the efficacy of 
laparoscopic celiac plexus 
block. 
 
Quantitative; 
quasi-
experimental 
study 
Unresectable 
pancreatic 
malignancy with 
significant pain 
(n=20) 
Symptom intensity:  
a) Baseline: Mean pain score: 7.8/10 [BPI] and 65.8/100 [EORTC QLQ-
C30]. 
b) Follow-up:  pain, insomnia, and appetite loss improved significantly 4 
weeks after procedure [EORTC QLQ-C30]. 
Bernhard 
(2010) 
To investigate the 
prognostic value of QOL 
relative to tumor marker 
carbohydrate antigen in 
patients with APC 
receiving chemotherapy. 
Quantitative; 
predictive 
correlational 
study 
APC patient treated 
in an 
international phase 
III trial  
(n=295) 
Symptom intensity:  
Baseline: Median pain score for patients with increased tumor marker 
concentration (n=247): 83/100 and for patients with normal tumor marker 
concentration (n=48): 88/100; median tiredness score for patients with 
increased tumor marker concentration: 62/100 and for patients with 
normal tumor marker concentration: 70/100; median physical well-being 
score for patients with increased tumor marker concentration: 71/100 and 
for patients with normal tumor marker concentration: 72/100; median 
mood score for patients with increased tumor marker concentration: 
63/100 and for patients with normal tumor marker concentration: 59/100 
[LASA] 
Associating factors:  
a) Poor performance associated with worse symptoms including mood, 
tiredness, and pain. 
b) Pain and tiredness can predict survival independently.   
Bye (2012) To assess energy intake, 
weight loss and symptoms 
during the disease course 
and investigate 
associations between 
symptoms and energy 
intake. 
Quantitative, 
descriptive 
correlational 
study  
APC (n=39) Symptom intensity:  
a) Baseline: 37% to 63% patients had moderate to severe intensity of 
almost all symptoms [ESAS]. Flatulence, oral dryness and indigestion 
were the most frequent symptoms reported [QLQ-PAN26]. 
b) Follow-up: minor changes from baseline [ESAS & QLQ-PAN26] 
Associating factors:  
c) The correlations between energy intake and symptoms become 
stronger when disease progress: At 2-month follow-up, there is strong 
negative correlation between energy intake, appetite loss, oral dryness 
and fatigue. At 3-month follow-up, there is a strong negative 
correlation between energy intake and appetite loss, pain, dyspnea and 
flatulence.  
Braun 
(2013) 
To examine if baseline 
QoL and QoL changes 
Quantitative; 
descriptive 
Stage IV pancreatic 
cancer (n=186) 
Symptom intensity:  
Table(s)
from baseline until 3 
months after treatment 
could predict survival in 
patients with stage IV 
pancreatic cancer. 
correlational 
study 
a) Baseline: In average, patients experienced fatigue (41.8/100), pain 
(37.6/100), insomnia (36.6/100), and appetite loss (33.3/100) at 
moderate level [EORTC QLQ-C30]. 
b) Follow-up: fatigue and appetite loss worsen; pain and insomnia 
improved 3 months after treatment.  
Associating factors:  
c) Physical function, social function, fatigue, pain, dyspnea, and global 
health were predictive of survival. 
Crippa 
(2008) 
Evaluate the QoL and 
survival in patients with 
different stages of 
pancreatic cancer  
Quantitative; 
descriptive 
longitudinal 
study 
Pancreatic cancer 
(n=92; n of APC: 
64) 
Symptom intensity:  
APC patients tended to report more abdominal pain than patients had 
localized pancreatic cancer 
Dobratz 
(2009) 
To determine if 
nociceptive/ neuropathic 
pain could be identified 
by word selections  
Quantitative; 
descriptive 
study  
Advanced cancer 
patients received 
home-based 
hospice services 
(n=76; n of APC: 
4) 
Symptom quality: 
APC patients showed no distinct pain pattern (nociceptive or neuropathic) 
in their word choices while colon and liver cancer selected words that 
described 2 types of nociceptive (visceral, somatic) pain and prostate 
cancer patients noted somatic pain. 
Gao (2014) To evaluate the 
effectiveness of standard 
pain medication with or 
without NCPB  
Quantitative; 
quasi-
experimental 
study 
Unreseactable 
pancreatic cancer 
with pain (n=100) 
Symptom intensity:  
a) Baseline: in average, patients experienced fatigue and constipation at 
moderate level; pain, insomnia, and appetite loss at severe level 
[EORTC QLQ-C30]. 
b) Follow-up: pain, appetite loss, and insomnia improved significantly 3 
month post-therapy. 
Labori 
(2006) 
To describe prospectively 
the prevalence and 
severity of disease-related 
symptoms, QoL and need 
for palliative care in 
patients with APC 
Quantitative, 
descriptive 
longitudinal 
study  
APC (n=51) Symptom intensity:  
a) Baseline: fatigue and loss of appetite have highest mean score [ESAS 
& EORTC QLQ-C30]. Compared to general population, APC 
patients’ fatigue, pain, and appetite loss were significantly impaired 
[EORTC QLQ-C30]. 
b) Follow-up: increasing intensity of all symptoms the last 8 weeks 
before death, except for pain at rest and appetite [ESAS]. 
Laird 
(2011) 
To examined whether 
pain, depression, and 
fatigue exist as a 
symptom cluster in 
advanced cancer patients 
with cachexia and might 
be related to the presence 
of systematic 
inflammation 
Quantitative; 
comparative 
descriptive 
study 
Cachectic, 
advanced, 
unresectable cancer 
(n=654; n of APC: 
181)  
Timing dimension of symptom:  
a) Pain, depression, and fatigue is an identifiable symptom cluster in a 
cohort of cachexic cancer patients. The prevalence of symptom cluster 
of pain, fatigue and depression is greater in lung and GI cancer than 
APC [EORTC QLQ-C30]. 
Associating factors: 
b) For all patients, Pain, depression, and fatigue symptom cluster was 
associated with reduced physical functioning, but not related to CRP. 
Moningi 
(2015) 
To evaluate how QoL 
change based on clinical 
stage at presentation to 
the JH Pancreas 
Multidisciplinary 
Clinic 
Quantitative; 
descriptive 
study  
Patients visited the 
Johns Hopkins 
Pancreas 
Multidisciplinary 
Clinic (n=77; n of 
APC: 39) 
Symptom intensity:  
a) APC patients had significantly worse indigestion, flatulence, and diet 
limitations than patients with non-advanced stage [EORTC QLQ-
PAN26]. 
Associating factors: 
b) Patients with lower performance status had significantly worse 
pancreatic pain and digestive symptoms. 
Muller 
(2008) 
To evaluate a palliative 
surgical bypass procedure 
in patients with 
obstructive and 
intraoperative pancreatic 
cancer 
Quantitative; 
quasi-
experimental 
study 
Non-resectable 
pancreatic cancer 
(n=136) 
Symptom intensity:  
a) Baseline: 26% patients had moderate- to severe- pain. 
Timing dimension of symptom:  
b) Baseline: 51% patients had daily pain 
Associating factors: 
c) Daily pain associated with significant poor survival after bypass 
surgery and was a significant independent indicator of poor survival.   
Reyes-
Gibby 
(2007) 
To assess symptoms of 
patients with locally 
advanced pancreatic 
cancer receiving 
chemoradiation to 
determine the prevalence, 
and co-occurrence, of 
symptoms and to identify 
the extent to which 
symptoms interfered with 
function 
Quantitative, 
descriptive 
correlational 
study  
Locally advanced 
pancreatic cancer 
(n=43) 
 
Symptom intensity:  
a) Baseline: 95% of patients reported at least one of the 13 symptoms. 
The most commonly reported symptoms of moderate to severe 
intensity were lack of appetite (24%), pain (19%), fatigue (19%), and 
sleep disturbance (10%) [MDASI].  
b) Follow-up: An increase in patients reporting moderate to severe 
fatigue, nausea, and sleep disturbance during chemoradiation. The 
proportion of patients reporting moderate to severe symptoms of pain, 
lack of appetite, fatigue and sleep disturbance significantly decreased 
after 94 days of chemoradiation. 
Associating factors:  
c) Presence of a comorbid medical condition was a signiﬁcant factor for 
symptom intensity. Lack of appetite, fatigue, sleep, and pain were the 
symptoms that accounted for variation in walking, activity, mood and 
enjoyment of life.  
Romanus 
(2012) 
To evaluate health-related 
QoL in patients with APC 
participating in a 
multicenter, double-blind, 
randomized trial 
Quantitative; 
quasi-
experimental 
study 
Inoperable 
pancreatic cancer 
with ECOG status 
of 0-2 (n=186) 
Symptom intensity:  
a) Baseline: compared with the U.S. general population, a larger 
proportion of APC patients reported problems in pain/discomfort 
(78%) and anxiety/depression (53%) [EQ-5D]. 
b) Follow-up: symptoms of anxiety/depression and pain/discomfort 
improved. 
Seicean 
(2013) 
To evaluate the safety and 
efficacy of EUS-CPN in 
patients with painful 
unresectable pancreatic 
cancer 
Quantitative; 
quasi-
experimental 
study  
Inoperable, chemo-
naïve body-tail 
pancreatic cancer 
receiving opioid 
analgesia (n=32) 
Symptom intensity:  
a) Follow-up: pain improved significantly in 75% patients [BPI]. 
Associating factors:   
b) After procedure, ratings of “pain interfering with general activity, 
walking, work, mood, enjoyment of life, relations with others, and 
sleep” improved significantly. Physical, functional, and emotional 
well-being also improved significantly [FACT]. 
Stefaniak 
(2005) 
To compare the 
effectiveness of two 
invasive pain treatments 
(NCPB & VSPL) to a 
control group concerning 
pain and QoL  
Quantitative; 
quasi-
experimental 
study 
Inoperable 
pancreatic cancer 
with pain 
(n=59) 
Symptom intensity:  
(a) Follow-up: Both methods of invasive pain treatment resulted in 
significant reduction of pain and fatigue.  
Associating factors:  
(b) Physical, emotional and social well-being improved significantly only 
in NCPB group. 
Walter 
(2011) 
To compare QoL of 
patients with APC who 
were given palliative 
resection or double loop 
bypass surgery 
Quantitative; 
quasi-
experimental 
study 
APC (n=196) Symptom intensity:  
(a) Baseline: the average intensity level of appetite loss, insomnia, pain, 
fatigue, dyspnea, constipation, and diarrhea is moderate. 
(b) Follow-up: Palliative resection group had significantly increased 
dyspnea at discharge; increased nausea, dyspnea, constipation, and 
diarrhoea at 3 months after surgery. Appetite loss was more 
aggravated in double loop bypass group at 6 months after surgery. 
 
Abbreviations: APC, advanced pancreatic cancer; ECOG, Eastern Cooperative Oncology Group performance; ESAS, Edmonton Symptom Assessment Scale; 
EORTC QLQ-C30, European Organization for Research and Treatment of Cancer core module; EORTC QLQ-PAN26, European Organization for Research 
and Treatment of Cancer pancreatic cancer module; EQ-5D, European Quality of Life-5 Dimensions; FACT, Functional Assessment of Cancer Therapy; EUS-
CPN; Endoscopic ultrasound-guided celiac plexus neurolysis; LASA, Linear Analog Scale Assessment; MDASI, M.D. Anderson Symptom Inventory; NCPB, 
neurolytic coeliac plexus block; JH, Johns Hopkins; VSPL, videothoracoscopic splanchnicectomy; QoL, quality of life. 
Table 2. Symptoms Measured by EORTC QLQ-30/Pan26, EQ-5D, ESAS, FACT-G/Hep, 
LASA, and MDASI 
 
         
Instruments 
 
 
Symptoms 
EORTC  ESAS EQ-5D FACT LASA MDASI 
Core 
module 
(QLQ-30) 
 
Pancreatic 
cancer module 
(PAN26) 
  General 
module 
(G) 
hepatobiliary 
module 
(Hep) 
  
Pain  X X X  X  X  X    X 
Loss of 
appetite  
X     X   X 
Fatigue/ 
lack of 
energy 
X  X   X  X  X  X 
Sleep X       X 
Respiratory X  X      X 
Oral 
dryness 
 X     X   X 
Test change   X     X    
Digestivea X X X   X  X   X 
Numbness         X 
Senses of 
well-being 
  X  X     
Anxiety   X  X    X   
Depression/ 
sadness 
X  X  X  X   X  X 
Emotional 
distress/ 
mood 
disturbance 
       X 
Stress        X  
Life 
enjoyment 
       X 
Fear X  X        
Worry X    X    X 
Drowsiness    X      X 
Satisfaction  X     X     
Sense of 
meaning 
      X   
Relationship 
with God 
      X   
Hope      X     
 
Abbreviations: EORCT, European Organization for Research and Treatment of Cancer; ESAS, Edmonton 
Symptom Assessment Scale; EQ-5D, European Quality of Life-5 Dimensions; FACT, Functional Assessment of 
Cancer Therapy; LASA, Linear Analog Scale Assessment; MDASI, M.D. Anderson Symptom Inventory. 
a Digestive symptoms includes nausea and vomiting, flatulence, altered bowel movement and indigestion 
Table 3.  Symptoms and Problematic Symptoms Identified by Reviewed Studies and Corresponding Instrumentsa 
 
 Bye  Labori  Braun Gao Larid  Allen Moningi Walter Stefaniak  Crippa  Seicean  Reyes-
Gibby  
Romanus Dobratz Muller Bernhard 
P
h
y
si
ca
l 
Pain  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  
Loss of 
appetite  
X  X  X  X  X  X       X      
Fatigue/ 
lack of 
energy 
X  X  X X  X  X   X  X   X  X     X  
Sleep   X X  X  X      X  X      
Respiratory   X X  X  X       X      
Oral 
dryness 
X  X           X      
Test change  X                 
Digestiveb X  X  X  X  X  X  X     X  X      
Numbness            X     
P
sy
ch
o
lo
g
ic
al
 
Senses of 
well-being 
X  X        X         
Anxiety X  X            X    X  
Depression/ 
sadness 
X  X       X    X  X  X    X  
Emotional 
distress/ 
mood 
disturbance 
           X      
Stress                 X  
Life 
enjoyment 
          X       
Fear of 
future 
health 
problems 
      X           
Instruments   EORTC QLQ-C30 
& PAN26 
 ESAS 
EORTC QLQ-C30 
 
 EORTC 
QLQ-
C30 & 
PAN26 
 BPI 
EORTC 
QLQ-
PAN26 
EORTC 
QLQ-C30 
 EORCT 
QLQ-
C30 
 FACT-
G 
 FACT-
G 
 FACT-
Hep 
 FACT-
G 
 BPI  
MDASI EQ-5D McGill 
Melzack 
Pain 
Questio-
nnaire 
Single 
item of 
pain 
intensity 
and 
frequency 
LASA 
Operational 
definition of 
intensity levels 
[EORTC] 
M: ≥33.3; S:≥66.7 
[ESAS] 
M-S: ≥4 
[EORTC] 
M: ≥33.3; S:≥66.7 
 
 
Pain, 
fatigue, and 
depression 
respectively: 
M: ≥ 50, ≥ 
60, ≤70 
S: ≥60, ≥70, 
≤50 
- - [BPI] M: 
4-6; S:≥7 
M-S: 
≥5 
- - - - 
Determination of the 
relatively 
More 
than 
half 
M 
intensity 
on 
M intensity on EORTC - - - - Top 3 
highest 
Symptoms 
reported 
by more 
- - Compared 
to other 
problematic 
symptoms 
reported 
M-S 
intensity 
ESAS 
or 
EORTC 
mean 
score 
than half 
of the 
patients    
examined 
symptoms 
 
Abbreviations: BPI, Brief Pain Inventory; EORCT QLQ-C30, European Organization for Research and Treatment of Cancer core module; EORCT QLQ-PAN26, European 
Organization for Research and Treatment of Cancer pancreatic cancer module; EQ-5D, European Quality of Life-5 Dimensions; ESAS, Edmonton Symptom Assessment Scale; 
FACT-G, Functional Assessment of Cancer Therapy general module; FACT-HEP, Functional Assessment of Cancer Therapy hepatobiliary module; LASA, Linear Analog Scale 
Assessment; M, Moderate; MDASI, M.D. Anderson Symptom Inventory; S, severe. 
a Shading cells represent relatively problematic symptoms  
b Digestive symptoms includes nausea and vomiting, flatulence, altered bowel movement and indigestion 
  
 
 Id
en
ti
fi
ca
ti
o
n
 
S
cr
ee
n
in
g
 
E
li
g
ib
il
it
y
 
In
cl
u
d
ed
 
Records identified through 
database searching 
(n=916) 
Additional records 
identified through in 
reference lists (n=1) 
Records after duplicates removed 
(n=826) 
Abstract screened for eligibility 
(n=337) 
Full-text articles assessed for screened for 
eligibility  
(n=44) 
Study included in integrative review 
(n=16) 
 
Records with irrelevant titles (n=489) 
Records excluded (n=293) 
 Not report results specific to APC 
population: 128 
 Non-empirical, non-peer-
reviewed or review articles: 106 
  Not include patient-reported 
symptoms: 47 
 Only addressed symptoms related 
to specific drug or procedure: 12 
Full-text articles excluded (n=29) 
 Not include patient-reported 
symptoms: 11 
 Only address symptoms 
related to specific drug or 
procedure: 11 
 Not report results specific to 
advanced pancreatic cancer 
population: 6 
 Not English:1 
Figure 1. PRISMA Diagram of Search Results and Screening Process 
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